Panacea Biotech has received an update to its UNICEF contract for supplying the WHO pre-qualified pentavalent vaccine, Easyfive-TT (DTwP-HepB-Hib), for 2023-2027.
The contract value for 2026 has increased by $2.55 million (about ₹23 crore) to $16.8 million. For 2027, it has risen by $2.70 million (around ₹24 crore) to $15.18 million. Additionally, the company got a new award for 2027 worth $3.68 million (≈₹33 crore).
Also Read: Manish Sonthalia bets on premium consumption, capital markets, and rate sensitives for 2026
Earlier in October, UNICEF also placed a significant order for polio vaccines. Panacea Biotec received the letter of award (LoA) as part of a long-term agreement to supply bOPV in 10 and 20-vial presentations to the UN agency from April 1, 2026, to March 31, 2030.
The shares of Panacea Biotech closed at ₹359.50, up 0.93% on the NSE today, December 24.
